Join Growin Stock Community!

Zoetis inc.ZTS.US Overview

US StockHealthcare
(No presentation for ZTS)
My Watchlist

Ticker

Value

empty

There is no following symbol in this watchlist.

ZTS AI Insights

ZTS Overall Performance

ZTS AI Analysis & Strategy

AI Strategy

Browsing restrictions can be lifted for a fee.

ZTS Recent Performance

-2.72%

Zoetis inc.

0.05%

Avg of Sector

-0.31%

S&P500

ZTS PowerScanner

Introduction >>

Power Squeeze

Surfing Trend

1 Day

1 Week

1 Month

ZTS Key Information

ZTS Financial Forecast

chart

Browsing restrictions can be lifted for a fee.

QuarterlyEPS ForecastQoQMaxMin
2026Q1
2026Q2
2026Q3
2026Q4
2027Q1

ZTS Profile

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

Price of ZTS

ZTS FAQ

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

ZTS Earnings Table

Unit : USD

QTRNon-GAAP EPSEPS YoYEPS Surprise %SalesSales YoYSales Surprise %NPM
Current
2025Q4
2025Q3
2025Q2
2025Q1
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
6.07
PE Ratio (TTM)
21.78
Forward PE
19.41
PS Ratio (TTM)
6.10
PB Ratio
16.44
Price-to-FCF
24.89
METRIC
VALUE
vs. INDUSTRY
Gross Margin
71.84%
Net Margin
28.23%
Revenue Growth (YoY)
2.28%
Profit Growth (YoY)
4.04%
3-Year Revenue Growth
5.38%
3-Year Profit Growth
6.49%
METRIC
VALUE
vs. INDUSTRY
EPS (TTM)
6.07
PE Ratio (TTM)
21.78
Forward PE
19.41
PS Ratio (TTM)
6.10
PB Ratio
16.44
Price-to-FCF
24.89
Gross Margin
71.84%
Net Margin
28.23%
Revenue Growth (YoY)
2.28%
Profit Growth (YoY)
4.04%
3-Year Revenue Growth
5.38%
3-Year Profit Growth
6.49%

  • When is ZTS's latest earnings report released?

    The most recent financial report for Zoetis inc. (ZTS) covers the period of 2025Q4 and was published on 2025/12/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating ZTS's short-term business performance and financial health. For the latest updates on ZTS's earnings releases, visit this page regularly.

  • Where does ZTS fall in the P/E River chart?

    According to historical valuation range analysis, Zoetis inc. (ZTS)'s current price-to-earnings (P/E) ratio is 19.84, placing it in the Undervalued zone on the P/E River chart. This level indicates that the market's expectations for future earnings are already reflected in the share price, with the valuation currently leaning conservative. Investors are advised to further examine the company's fundamentals and its position in the industry cycle to validate whether the valuation is justified.

  • What is the operating profit of ZTS?

    According to the latest financial report, Zoetis inc. (ZTS) reported an Operating Profit of 818M with an Operating Margin of 34.27% this period, representing a growth of 4.47% compared to the same period last year. Operating Profit reflects the company's core business efficiency and cost control, making it a key indicator for evaluating operational strength and profitability.

  • How is ZTS's revenue growth?

    In the latest financial report, Zoetis inc. (ZTS) announced revenue of 2.39B, with a Year-Over-Year growth rate of 3.02%. Revenue growth can be driven by product mix changes, market share expansion, price adjustments, or international market penetration. Investors should also monitor gross margin and regional revenue distribution for a comprehensive view of growth quality and sustainability.

  • How much cash does ZTS have?

    At the end of the period, Zoetis inc. (ZTS) held Total Cash and Cash Equivalents of 2.31B, accounting for 0.15 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.

  • Does ZTS go with three margins increasing?

    In the latest report, Zoetis inc. (ZTS) achieved the “three margins increasing” benchmark, with a gross margin of 70.2%%, operating margin of 34.27%%, and net margin of 25.3%%. This demonstrates improvement in profitability, which is a key signal for fundamental analysis. Investors should consider margin trends alongside other financial indicators to assess ZTS's profit trajectory and future growth potential.

  • Is ZTS's EPS continuing to grow?

    According to the past four quarterly reports, Zoetis inc. (ZTS)'s earnings per share (EPS) shows a steady growth trend, with the latest EPS at 1.38. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.

  • What is the FCF of ZTS?

    Zoetis inc. (ZTS)'s Free Cash Flow (FCF) for the period is 731M, calculated as Operating Cash Flow minus Capital Expenditures, representing a rise of 6.1% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.